(Q36099419)

12 August 2017

1 reference

title

Agents in development for the treatment of diabetic nephropathy. (English)

1 reference

12 August 2017

3

Josephine M Forbes

1 reference

12 August 2017

Kei Fukami

1

1 reference

PubMed ID

15833059

12 August 2017

Mark E Cooper

series ordinal

2

1 reference

PubMed ID

15833059

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

279-294

1 reference

12 August 2017

3

1 reference

Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Advanced glycosylation end products in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Renoprotective effects of a novel inhibitor of advanced glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Current therapies and emerging targets for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Pimagedine: a novel therapy for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Therapeutic potential of breakers of advanced glycation end product–protein crosslinks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Hyperglycemia, Polyol Metabolism, and Complications of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Plasma Vasopressin in Uncontrolled Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Thirst and plasma levels of vasopressin, angiotensin II and atrial natriuretic peptide in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Molecular mechanisms of diabetic renal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Angiotensin II increases connective tissue growth factor in the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The time has come to target connective tissue growth factor in diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Function and localization of urate transporter 1 in mouse kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Inhibition of nuclear factor-kappaB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

Mitogen-activated protein kinases as glucose transducers for diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

The prevention or delay of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

High Levels of Glucose Stimulate Angiotensinogen Gene Expression Via the P38 Mitogen-Activated Protein Kinase Pathway in Rat Kidney Proximal Tubular Cells* *This work was supported by grants from the Medical Research Council of Canada (MT-13420 to J

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.279

10.1517/13543784.14.3.279

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15833059